Our Technology
Innovative Technology. Oncology Focus.
Our Technology
CorriXR Therapeutics has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial therapeutic regimen for the treatment of solid tumors.
Our initial genetic pathway target is the NRF2 gene. The NRF2 protein is a global transcriptional regulator that functions to activate genes in response to cellular stress and is implicated in progression of solid tumors. Our objective is to use CRISPR-directed gene editing to disable NRF2 gene functions specifically in cancer cells. Our preclinical data in both cell and animal models confirms that the NRF2 gene is a viable target for a gene editing therapeutic for solid tumors.
The initial delivery system for this gene editing tool is a proven lipid nanoparticle approach that will evolve from direct injection into systemic delivery for other targets.
Novel Oncology Target for Gene Editing: NRF2 Pathway
The NRF2 protein is a global transcriptional regulator that functions to activate genes in response to cellular stress. NRF2 maintains homeostasis in terms of normal cell behavior but can also act as an oncogene and help tumor development.
Upregulation of NRF2 by deleterious mutations is found in several tumor types, especially in squamous cell lung cancer. Mutational activation of the KEAP1/NRF2 pathway is connected to therapy resistance.
CorriXR’s proprietary CRISPR/Cas is designed to specifically knock-out the target NRF2 genes in tumor cells, but not in healthy cells.
In human-derived squamous NSCLC in vitro and in vivo animal studies, our data show that disabling NRF2 by gene editing leads to cell death and tumor shrinkage in combination with chemotherapy drugs.
CorriXR Therapeutics has developed a broad-based gene editing platform that is uniquely focused on Oncology. A positive INTERACT meeting was completed with the FDA requesting that we strongly consider a basket trial to include lung, esophageal, and head and neck squamous cell carcinoma.
Contact Us
Reach out to discuss partnerships to advance our technology.